ICON Selected by the FDA to Validate Patient-Reported Outcome Endpoints for Antibacterial Drug Trials

Read more

CTT Pharmaceutical Holdings and CanniMed Therapeutics Inc. Complete Exclusive Canadian Licensing Agreement

Read more

Immune Pharmaceuticals Announces the launch of REMAIN

Read more

FDA accepts Intellipharmaceutics’ NDA for Rexista to treat moderate to severe pain

Read more

Momenta announces FDA warning letter to contracted Glatopa’s fill/finish manufacturer

Read more

Arix Bioscience raises £100m in IPO

Read more

Health Canada Approves Otsuka and Lundbeck’s REXULTI

Read more

Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery

Read more

Imprimis Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility

Read more

Takeda acquires Ariad Pharmaceuticals

Read more